Company intelligence / Profile preview

Oculogenex

La Habra, California, United Statesoculogenex.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

Oculogenex is developing a novel adeno-associated viral (AAV) gene therapy for degenerative retinal diseases. Preclinical data show the approach enhances resistance to cellular stress, repairs damage, increases cell lifespan, and may activate dormant retinal stem cells. The company is preparing for Phase I clinical trials targeting dry AMD and related conditions. No active clinical trials are currently listed on ClinicalTrials.gov.

Therapeutic areas: Ophthalmology
Modalities: Gene therapy (AAV-mediated gene transfer)
Industry: Biotech

Drug pipeline

1 asset

OCLX-001

Preclinical

Partnerships

Forge Biologics (AAV process development and manufacturing partnership)ISS National Laboratory/NASA collaboration for space-based research model of AMD progression

Beyond the preview

Go deeper on Oculogenex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oculogenex.

Explore the full profile